<DOC>
	<DOCNO>NCT02709746</DOCNO>
	<brief_summary>Evaluating efficacy vortioxetine 10 mg/day 20 mg/day versus placebo depressive symptom adolescent ( age ≥12 ≤17 year ) DSM-5™ ( Diagnostic Statistical Manual Mental Disorders , 5th edition ) diagnosis Major depressive disorder ( MDD ) .</brief_summary>
	<brief_title>Active Reference ( Fluoxetine ) Fixed-dose Study Vortioxetine Paediatric Patients Aged 12 17 Years With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>The patient male female , age ≥12 ≤17 year Screening ( patient turn 18 year study allow continue study ) . The patient Major depressive disorder ( MDD ) , diagnose accord DSM5™ . The patient CDRSR total score ≥45 Screening Visit Baseline . The patient CGIS score ≥4 Screening Visit Baseline The patient provide assent participation parent ( ) /legal representative ( ) sign Informed Consent Form . The patient participate clinical study &lt; 30 day prior Screening Visit . Other protocol define inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>paediatric patient</keyword>
</DOC>